The Skin Flint Podcast

Pododermatitis Paw-dcast Show Notes

(02:21) John invites Ursula to introduce herself. Ursula discusses her background and passion for pododermatitis, its prevalence, and its impact on dogs' quality of life.

(03:33) When asked to define pododermatitis, Ursula explains that it's inflammation of the paw skin, with a particular emphasis on chronic cases, known as C-PIF. She discusses the various signs to look out for, such as excessive licking, lameness, and specific changes in paw appearance as the condition progresses.

(05:31) Sue talks about the complexity of pododermatitis, and Ursula draws parallels with chronic otitis in terms of the multifaceted factors involved. She emphasises the importance of considering predisposing factors, primary causes including orthopaedic issues, secondary influences, and perpetuating factors in diagnosing and managing the condition effectively.

(06:57) Sue asks Ursula to explain how orthopaedic diseases can contribute to pododermatitis in dogs. Ursula explains that pain from orthopaedic conditions alters weight bearing, causing dogs to adjust their stance and potentially rub their paws together, leading to inflammation and abnormal walking patterns. She goes on to discuss specific orthopaedic diseases, including elbow dysplasia, hip dysplasia, and arthritis affecting joints such as toes, carpus, tarsus, elbows, hips, and the back. These conditions can disrupt normal weight distribution and contribute to the development of pododermatitis.

(08:35) Sue further illustrates with an example and Ursula emphasizes the importance of referring chronic cases to orthopaedic specialists for thorough examinations and imaging. She acknowledges the complexity of diagnosing older dogs with multiple affected areas, stressing the need for integrated care across disciplines to effectively manage pododermatitis.

(09:56) John asks if this is just dogs and Ursula confirms that while cats can also suffer from pododermatitis, the chronic form discussed, known as C-PIF, predominantly affects dogs and not cats. John then asks about breed predispositions, particularly in relation to posture-related issues in Labradors. Ursula elaborates that certain breeds, notably larger and heavier ones like bulldogs, French bulldogs, and pugs, are commonly affected. Labradors and Golden Retrievers also constitute a significant portion of cases. The characteristics such as short, bristly coats and broad, flat paws, may contribute to their susceptibility to the condition. Ursula notes that even without orthopaedic diseases, these breeds' anatomical traits appear to play a role in the development of pododermatitis.

(12:20) Sue reflects on a study involving bulldogs walking on pressure plates, noting that those without interdigital lesions tended to walk more upright. She emphasises that dogs with flatter feet and heavier builds are more prone to issues due to their posture, suggesting a correlation between anatomical features and pododermatitis. She further discusses how these factors influence investigation and treatment approaches. Ursula agrees, highlighting the significant role of allergies alongside orthopaedic diseases in pododermatitis cases. She notes the complexity in distinguishing between underlying orthopaedic conditions and inherent anatomical predispositions in certain breeds. Ursula shares a case involving a dog initially treated for allergies, later developing orthopaedic issues that exacerbated pododermatitis, illustrating the interplay between these factors.

(14:47) Sue outlines the investigative process, starting with a comprehensive history and dermatological examination, incorporating orthopaedic evaluations based on findings. Ursula explains her approach, emphasising the importance of ruling out issues, particularly Demodex, through rigorous testing methods. She discusses predisposing factors such as weight and breed characteristics, and systematically examines for primary diseases like allergies, orthopaedic issues, and endocrine disorders. Ursula stresses the need to assess secondary infections and carefully inspect paw conditions, especially ventrally, to identify specific dermatological and orthopaedic indicators.

(18:24) Sue asks about infection management in pododermatitis cases. Ursula explains that for superficial cases of pododermatitis, she primarily employs topical treatments. However, in chronic cases where deep pyoderma is present, systemic antibiotics are often necessary. She emphasises the importance of not relying solely on antibiotics without addressing underlying factors, as this can lead to recurring infections and antibiotic resistance. In deciding whether to use systemic antibiotics, Ursula considers the overall treatment plan. If surgery such as laser therapy is planned, she may opt against systemic antibiotics. For cases where medical therapy alone may suffice, she stresses the need for culture and sensitivity testing to target treatment effectively and minimise antibiotic use.

(20:17) John questions Ursula about the approach to treating infections and determining underlying causes simultaneously. Ursula explains her concurrent approach, emphasising the urgency in addressing both infections and underlying conditions early on to improve the dog's quality of life.

(22:17) Sue asks about anti-inflammatory therapy options in pododermatitis and the efficacy of non-steroidal anti-inflammatories (NSAIDs) versus steroids, cyclosporine, tacrolimus, and anti-pruritic drugs like oclacitinib and lokivetmab.. Ursula details her approach, highlighting the need for potent anti-inflammatory agents in severe cases of pododermatitis. She explains that while drugs like oclacitinib can alleviate itching, they may not sufficiently address inflammation. For cases requiring robust anti-inflammatory action, Ursula often starts with systemic steroids and cyclosporine simultaneously, gradually tapering off steroids once cyclosporine takes full effect. She stresses the challenges and side effects associated with long-term steroid use, advocating for cyclosporine as a viable long-term treatment despite its delayed onset of action. Ursula discusses transitioning to topical therapies like tacrolimus or non-thinning glucocorticoids as conditions improve, aiming to minimise reliance on systemic medications over time.

(25:16) Sue asks about the complexities faced by Ursula when treating animals with multiple conditions. Ursula acknowledges the multifaceted nature of these cases, stressing the importance of weight management as a foundational step due to its lack of side effects. She emphasises the need for collaboration with orthopaedic specialists to address underlying orthopaedic diseases like elbow dysplasia early on. For pain relief and inflammation management in the feet, Ursula initially uses systemic steroids and cyclosporine, with a cautious approach to long-term steroid use.

(27:05) Sue asks about prioritising orthopaedic surgery to correct primary causes like ununited coronoid process before addressing pododermatitis. Ursula acknowledges this strategy, noting that while surgery can eliminate chronic factors perpetuating pododermatitis, the outcomes vary depending on the case's severity and the owner's preferences. She explains that surgical intervention in the paws may provide faster relief, especially when orthopaedic conditions are severe. However, she also highlights the challenge of reversing long-standing paw conditions even after correcting the primary cause. Ursula emphasises the importance of timing and individualised treatment plans tailored to each patient's specific needs and responses.

(29:14) John enquires about the feasibility of surgical procedures for pododermatitis in general practice versus referral settings. Ursula explains that surgical suitability depends on the general practitioner's expertise in dermatology, orthopaedics, and surgical techniques. For interdigital web surgery using traditional methods, like cold steel, she mentions the challenge of post-operative management due to necessary rigid bandaging. She contrasts this with CO2 laser surgery, highlighting its advantages such as reduced bleeding, pain, and swelling post-surgery due to sealed lymphatic and blood vessels and nerve endings. Ursula notes that CO2 lasers offer precise, fine-tuned tissue removal while preserving healthy dorsal skin, promoting healing by second intention without sutures. This approach aims to restore normal paw anatomy, crucial for long-term health. Ursula cautions against using diode lasers due to their higher collateral heat damage potential, unsuitable for delicate pododermatitis cases requiring precise tissue control.

(33:49) Sue summarises the distinctions between podoplasty and CO2 laser techniques: podoplasty involves excising interdigital tissue and suturing toes, whereas CO2 laser surgery delicately removes scar tissue and abnormal follicles, crucial for preventing recurrent infections. Ursula elaborates on using CO2 lasers in both painting and cutting modes depending on tissue conditions, emphasising its efficacy in restoring paw health through precise, controlled tissue removal.

(35:03) John concludes the discussion and Ursula emphasises the significance of regular examination of paw pads, especially in predisposed breeds or suspected allergic patients, urging veterinary professionals to involve owners in observing early signs like erythema. She stresses the value of early referral when cases become challenging, highlighting proactive management as key.

(37:52) Sue and John wrap up with their thoughts on this month’s guest, before John asks the team a question that’s been bugging him all episode…

Unleashed: The Dawn of the Leishmania

Intro

Chapter 1: The Attack of the Sandfly

3.17 Sue introduces the topic of leishmaniasis, and Christian describes leishmaniasis as a multisystemic disease affecting humans and animals, primarily dogs. He notes its prevalence in regions like the Mediterranean and its expansion due to climate change and imported infected dogs.

5.19 Sue questions whether leishmaniasis occurs naturally in the UK or is solely imported. Christian mentions reported cases in the UK, suggesting transmission via infected phlebotomine flies brought back by travelers from endemic regions. The conversation shifts to the sandfly vector responsible for transmitting leishmaniasis. Christian describes the sandfly as small, silent, and potentially painless, emphasizing its absence in the UK but the possibility of migration due to global warming. Christian advises against using repellents on dogs in the UK due to environmental concerns but stresses the importance of monitoring the situation, given he acknowledges the likelihood of sandflies reaching the UK in the future.

7.27 John queries if leishmaniasis can be transmitted by other vectors like fleas. Christian affirms that sandflies are the primary vector for the disease, although other potential vectors are suspected but not proven. John then asks if humans can contract the disease from infected dogs. Christian explains that with the vector absent in the UK, human transmission from dogs is unlikely. However, he emphasizes the importance of isolating positive dogs to prevent transmission through blood transfusion.

Chapter 2: The Haunting Symptoms and Diagnosis

9.11 The conversation then transitions to the clinical signs of leishmaniasis. Christian describes typical systemic symptoms such as anorexia, weight loss, lethargy, and mucous membrane pallor, along with some less common signs like polyuria and polydipsia. Christian also discusses characteristic skin lesions, including non-pruritic exfoliative dermatitis and erosive lesions. Sue adds her observations about the scaly appearance of affected dogs without itchiness, contrasting it with parasitic skin conditions. Christian concludes by stressing the importance of diagnostic assistance in accurately identifying the disease, especially considering its varied clinical presentations.

12.09 Sue brings up how leishmaniasis can affect nails, prompting Christian to elaborate on what clinicians might observe. He describes nails that grow unusually long and fast, resembling talons rather than being deformed. Christian notes that this sign is relatively rare in his experience, with scaly dermatitis or ulcerative dermatitis being more common presentations.

13.11 Sue then queries whether certain clinical presentations carry a better prognosis than others. Christian explains that prognosis depends on the severity of internal organ involvement, particularly kidney disease. The disease originates from the skin but can affect various body parts due to the immune system's reaction.

14.12 John asks how general clinicians diagnose it. Christian outlines that diagnosis relies on compatible clinical signs and specific clinical pathologies, notably anemia and changes in protein levels. While general practitioners can conduct serological tests, more specialized examinations may require referral to a laboratory. Christian emphasizes the importance of considering travel history and ruling out other conditions before treatment initiation.

16.40 Sue raises the issue of screening for leishmaniasis in dogs rescued from abroad, inquiring about the incubation period and when to start screening. Christian explains that the incubation period varies greatly, suggesting performing a quantitative serological test six months after returning from an endemic area. If positive, measures like using repellent and excluding the dog from blood transfusion banks are advised. Sue seeks more detail on the blood tests, and Christian elaborates on measuring the amount of Leishmania-specific antibodies using quantitative serological tests. These tests help detect high antibody levels, indicative of infection.

Advert Ditty

What products do we have now? Do we have a Zincoseb one, any shampoos?

Chapter 3: Eternal Vigilance Against the Parasite

18.55 John then asks about therapy options for positive cases. Christian emphasizes the goal of controlling clinical signs and pathological abnormalities, as complete parasite elimination is rare. Therapy typically involves a combination of leishmanicidal drugs, which aim to kill the parasite, and leishmaniostatic drugs, which maintain a low parasitic level, together aiming to reduce the parasitic load and prevent relapses. He notes the need for topical treatments alongside systemic therapy to manage symptoms like scaly skin.

22.00 John asks about drug availability and Christian mentions challenges in drug availability and potential side effects, particularly with drugs like allopurinol, which can cause adverse urinary effects. He recommends monitoring for crystal formation in the urine and considering alternative treatments if needed, highlighting emerging immunomodulatory drugs as promising options. However, his leishmanicidal drugs of choice would be allopurinol and meglumine antimonate.

23.55 Sue then asks about the expected response time to treatment and the monitoring process. Christian explains that clinical improvement can be seen in about four weeks with meglumine antimonate and two months with Miltefosine, an oral drug. Monitoring every three to four months is crucial, although antibody titres may take longer to decrease.

24.55 John asks about the lifelong management of the disease. Christian confirms that the drugs can be expensive and may need to be imported, emphasizing the importance of compliance and regular check-ups to improve prognosis.

25.51 Sue concludes by highlighting the role of primary care vets and dermatologists in managing the disease. She also enquires about alternative treatments like turmeric and herbal concoctions. Christian stresses the importance of evidence-based treatments and mentions dietary nucleotides and active hexose correlated compounds as effective alternatives.

27.29 Sue thanks Christian and expresses concern about the potential spread of leishmaniasis in the UK due to warmer summers and increased animal movements across borders.

Welcome to a new episode of the Skinflint Podcast, celebrating our impressive milestone of 10,000 downloads. This episode is a deep dive into the crucial role of sustainability in veterinary dermatology, presented to you by Nextmune UK and Elearning.Vetand featuring Monika Linek.

Chapter 1: Setting the Sustainability Stage 

(03:10) Sue introduces Monika to the podcast, who shares her experience as a German dermatologist and diplomat of the ECVD. Monika discusses her work in a referral practice in Germany and her involvement in "Parents for Future," advocating for climate justice and sustainability.

(05:20) Monika defines sustainability as meeting present needs without compromising future generations' ability to meet their own. It involves maintaining a balance to prevent depletion of natural resources and harm to ecosystems.

Sue emphasizes the importance of sustainability in preserving the Earth for future generations. Sustainable practices ensure a lasting and enduring system for future generations.

(06:40) Sue raises the issue of sustainability in veterinary dermatology practices and asks Monika about potential improvements. Monika highlights several areas for improvement, including reducing carbon footprint from energy use, transportation, and waste management.

(07:39) Monika acknowledges the challenges of telemedicine in veterinary dermatology due to the necessity of physical examinations. However, she sees potential in remote consultations for follow-ups or initial assessments, particularly for referring practices. Finding a balance between technology and quality care is crucial. Monika also notes telemedicine's ability to reduce clients' carbon footprint by minimizing travel, a point Sue agrees with, emphasizing its role in complementing traditional consultations and promoting sustainability.

Chapter 2: Navigating Sustainable Solutions

(10:19)  John asks about areas in veterinary dermatology that could reduce carbon footprint. Monika underscores the importance of considering the environmental impact of drugs, particularly antibiotics and anti-parasitics. She notes the shift towards antibiotic stewardship and the need to rethink the use of topical anti-parasitics like chlorhexidine. Monika emphasizes the necessity of rethinking and changing practices regarding drug usage to minimize environmental impact.

(12:32) John appreciates Monika's insights and finds them encouraging, as these considerations align with responsible veterinary practices. He delves into the choice between systemic and topical treatments in dermatology, seeking Monika's opinion on their sustainability. Monika discusses the need for susceptibility testing before antibiotic use and emphasizes the benefits of combining topical treatments with antibiotics to reduce treatment duration. She advocates for avoiding systemic antibiotics when possible, relying on topical treatments alone for superficial pyoderma.

Regarding alternatives to chlorhexidine, Monika suggests hypochlorous acid as a more environmentally friendly option. Sue agrees, highlighting the importance of effective yet eco-friendly alternatives that do not compromise animal health.

(16:28) The conversation shifts to the development of technologies like photonic therapy as potential replacements for topical treatments. However, Sue acknowledges the challenge of balancing efficacy, cost, and environmental impact in private veterinary practice. Monika points out the need to address the pricing of eco-friendly products, highlighting the broader systemic issues surrounding their accessibility and affordability.

Chapter 3: Practical Sustainability

(18:36) John raises a practical question about the disposal of unused medications and antiseptics. Monika mentions new guidelines in the UK for returning unused or expired antibiotics and medicines to clinics for proper disposal. She highlights the importance of implementing better waste disposal systems for medicines in the future.

Sue adds that the UK has an "antibiotic amnesty" campaign encouraging people to return unwanted antibiotics to designated drop-off points instead of disposing of them improperly. These drop-off points include pharmacies and veterinary clinics, which have appropriate methods for disposing of clinical waste.

(21:36) John raises the idea of reusing items in veterinary practice, such as scalpels and biopsy devices, instead of relying solely on single-use plastics. Monika suggests that while it may be challenging to revert to using glass syringes, there are still opportunities to explore reusable alternatives for certain items, such as surgical gowns and towels. Sue emphasizes the importance of putting pressure on manufacturers to produce more recyclable and sustainable products, even if it means paying a bit more.

When discussing sterilization methods, Sue acknowledges that there are various factors to consider, such as the environmental impact of disposing of sterilizing solutions. Monika suggests that methods like autoclaving could be more sustainable if powered by renewable energy sources like solar or wind power, reducing their carbon footprint.

(26:53) John reflects on the complexity of sustainability discussions within veterinary practice, noting that while there may not always be clear answers, the important thing is that people are actively engaging in conversations and considering sustainable practices. Monika raises concerns about greenwashing and emphasizes the need for genuine action rather than just slogans. Sue adds that changing habits can be challenging but underscores the importance of prioritizing sustainability in everyday actions, even those seemingly small, like shutting down computers.

(29:00) Shifting the conversation to dietary choices for animals, Sue asks about sustainable options for food trials, particularly considering allergies. Monika discusses the challenges of finding novel protein sources and suggests that home-cooked diets may be more sustainable, though caution is needed, especially with cats. She also highlights the need for transparency from pet food manufacturers regarding the carbon footprint of their products, echoing the call for informed decision-making and accountability in veterinary practice.

(34:35) Monika highlights three key tips for sustainable veterinary dermatology practice: rethinking antibiotic and antiparasitic use, addressing waste management through the waste hierarchy, and reducing paper consumption by embracing digital solutions. Sue acknowledges the importance of these tips, emphasizing their relevance for all veterinarians. John expresses gratitude to Monika for her insights and contribution to the discussion on sustainability in veterinary dermatology.

Chapter 1: "The Dermatological Agent: Ross's Malassezia Mission"

02.42 - John begins by welcoming Ross to the Skinflint podcast and acknowledges Ross's expertise in "Malassezia." He asks Ross to share his background and explain what Malassezia is.

Ross introduces himself as a professor of veterinary dermatology, detailing his experience in farm practice and later transitioning to small animal practice. He pursued further studies and a Ph.D. specifically focusing on Malassezia, and so has been interested in them for more than 30 years.

03.44 - John asks Ross to elaborate on Malassezia, describing it for listeners who might not be familiar with the term.

Ross explains that Malassezia is a group of yeast found naturally on the skin of various mammals and birds, thriving in lipid-rich environments. It typically exists as a commensal organism on the skin but can become an opportunistic pathogen, leading to dermatitis and otitis in dogs and occasionally in cats and horses.

05:27 - Sue asks if Malassezia is the same across different species or if there are variations.

Ross explains that there are 18 known species of Malassezia, each potentially adapted to a specific host. He discusses examples like M. cunicui in rabbits, M. caprae in goats, and M. equina in horses. He notes M. pachydermatitis as the dominant species in dogs, which is unique as it can grow on routine culture media, unlike other species requiring lipid supplementation. In contrast, cats may have different species like M. nana and M. slooffiae, among others, leading to variations in yeast colonisation. There's a discrepancy between what's identified molecularly and what's observed in cultures, particularly in dogs, highlighting an unexplained scientific disparity.

Chapter 2: "Species Confidential: Malassezia's Breed of Intrigue"

8.44 - John asks Ross about the location of Malassezia on animals.

Ross mentions that, in dogs, Malassezia is predominantly found in web spaces (75-80%), lip fold regions (similar proportion), and ear canals (about one-third). Lower levels are detected on the trunk, axilla, groin, and dorsum due to their warm, moist nature.

10.00 - John inquires about identifying Malassezia in cytology with dermatology tests like tape strips or impression smears.

07:35.54 - Ross confirms that Malassezia has a characteristic peanut-shaped morphology, identifiable under microscopy, usually abundant in specimens obtained from areas like a friendly basset hound's ear wax or neck fold wax, which are good teaching examples.

08:17.63 - Sue asks Ross about determining the relevance of Malassezia presence in ears or skin.

Ross explains breed-specific variations in normal yeast population, how certain breeds might have high yeast counts without causing issues, and that the anatomical site also influences yeast populations. He notes that there's no clear clinical cut-off for relevance; treatment response often helps assess its significance, as excessive yeast might not always correlate with clinical symptoms.

14.39 - John asks Ross about the clinical signs indicating an overgrowth of Malassezia.

Ross explains that signs like inflamed or greasy skin, particularly in folded areas, ears, neck, or groin, are indicative of a potential Malassezia issue, especially in predisposed breeds (he names some).

16.48 - Sue asks Ross about Malassezia as a primary or secondary disease and its relation to underlying issues.

Ross mentions that Malassezia is a commensal yeast and when it causes disease, it's often secondary to an underlying problem, involving immune system imbalances or hypersensitivity responses. Ross confirms that even in breeds prone to Malassezia, like Basset Hounds, there's usually an underlying cause for yeast proliferation. He mentions high Malassezia colonisation in mucosal populations of Basset Hounds, indicating more than just skin folds contributing to the issue.

Chapter 3: "Fungal Intrigue and Secret Signs: Unravelling Malassezia's Plot"

20.33 - John discusses the common misconception regarding skin folds and Malassezia issues in certain dog breeds with Ross. They touch upon the possibility of Malassezia hypersensitivity, its occurrence in certain dogs, and its association with atopic dermatitis.

Ross explains that while Malassezia hypersensitivity exists, its clinical presentation might not always correlate with immediate hypersensitivity reactions. He discusses intradermal testing in Bassett Hounds and the presence of IGE reactivity in some dogs, especially those with atopic tendencies.

25.19 - Sue asks Ross about primary care veterinary surgeons' preferred methods for diagnosing Malassezia dermatitis. Ross recommends simple techniques like ear swabs, tape strips, and microscopic examination for diagnosing Malassezia in primary care settings.

26.21 – John asks about whether this can be transferred between pets and humans.  Ross discusses the potential for Malassezia transfer between pets but emphasises that transferring Malassezia Pachydermatitis from pets to healthy owners is quite unlikely. He mentions instances in neonatal care units where Malassezia-related infections traced back to pet dogs have been observed, emphasising the importance of handwashing in preventing transmission.

28.18 - John inquires about treatment recommendations for Malassezia infections. Ross emphasises the accessibility of Malassezia yeasts for topical treatment and discusses the practical challenges in applying topical therapy to dogs with dense hair coats. He highlights the efficacy of 2% miconazole/2% chlorhexidine and 3% chlorhexidine shampoos based on consensus guidelines, alongside systemic treatments like itraconazole and ketoconazole.

34.29 - Sue asks Ross about the role of steroids in managing chronic Malassezia otitis and skin infections. Ross explains the importance of oral prednisolone for reversing stenosis in the ear canal and discusses the use of steroids in chronic Malassezia dermatitis, particularly in cases with allergic components, thickened skin, and hyperpigmentation.

39.44 - Ross provides a summary of the approach to Malassezia otitis externa and skin infections, suggesting a varied approach depending on the severity of the condition. He highlights situations where combining prednisolone with antifungal treatment may be necessary.

Sue and John express their gratitude to Ross for his expertise and wealth of information on Malassezia. They acknowledge the complexity of the subject and appreciate the insights shared during the discussion.

John introduces the podcast and the co-hosts for this conversation; the guest on this episode is RCVS Specialist in Veterinary Oncology, David Killick.

Chapter 1 – Little Miss Diagnosis

David's Background:

2.14 - David began in general practice in 2003 and later specialized in medical oncology at the University of Liverpool, earning a PhD at the RVC in London. He is now the professor of veterinary oncology at the University of Liverpool.

Malignant vs. Benign:

3.19 - Benign growths stay localized, mostly causing no problems during a pet's lifetime, while malignant growths can invade nearby tissues and spread.

4.49 - Approximately 40-50% of skin growths in dogs are malignant.

Investigate All Lumps

5.30 - Investigate All Lumps: Investigating all skin lumps is essential, even if no immediate action is taken. Initial investigation involves history-taking and examination, looking for signs like attachment to underlying structures or enlarged lymph nodes.

Biopsy Importance

8.05 - Diagnostic biopsy samples, including fine needle aspiration (FNA), are invaluable in veterinary medicine. FNA is minimally invasive, providing initial insights in 80-90% of cases. It may not offer a precise diagnosis but guides further steps.

David suggests fine needle aspiration as a cost-effective initial diagnostic tool, emphasizing its utility in informed decision-making. Other options include incisional and excisional biopsies, each with its own considerations regarding risks and benefits.

By prioritizing fine needle aspiration, veterinarians can efficiently navigate the path toward accurate diagnoses and appropriate treatment plans.

Factors Influencing Animal Skin Tumours

11.05 - Sue inquires about factors influencing susceptibility to skin tumours in animals, such as age, breed, and sex. David discusses breed-related associations with specific diseases in veterinary oncology, citing mast cell tumours in bulldogs, boxers, and retrievers. He mentions melanomas more common in Scotties and Schnauzers and highlights characteristics like rapid growth and tissue attachment raising malignancy concerns.

Identifying Common Benign Lumps Visually

13.18 - John seeks insights into visually identifying common benign lumps. David notes some, like skin tags, papillomas, and sebaceous adenomas, can be recognized by appearance. Skin tags are outgrowths, papillomas breed-specific, and sebaceous adenomas common in aging Cocker Spaniels. David advises monitoring, measuring, and fine needle aspiration for accurate identification.

Understanding Pigmented Tumours in Dogs, Especially Melanomas

16.33 - Sue asks about pigmented tumours in dogs, melanomas specifically. David explains not all pigmented tumours are melanomas. Dark or black lesions suggest melanomas, including malignant melanoma and benign melanocytoma. Skin melanomas may require removal if melanocytes are detected, with digital and oral melanomas requiring active management.

Identifying Melanocytes in Fine Needle Aspirations

18.00 - Sue questions melanocyte identification in fine needle aspirations. David notes pigmented tumours are usually melanomas, with characteristic black granules in cells. He mentions amelanotic melanomas' rare occurrence, especially in oral cases.

Chapter 2 – Introducing Mr Mast Cell

Insight into Mast Cell Tumours

18.52 - John seeks insight into mast cell tumours (MCTs). David explains their origin from mast cells, which release histamine and cause itchiness and redness. MCTs may periodically change size upon palpation. They are common in dogs, especially specific breeds, potentially requiring multiple management due to recurrence.

Using Fine Needle Aspirations (FNAs) for Diagnosis and the Role of Veterinary Nurses

22.10 - John inquires about using fine needle aspirations (FNAs) for diagnosis and the role of veterinary nurses in interpreting samples. He wonders if preliminary assessments in practice are acceptable due to budget constraints and potential risks. David encourages practitioners, including vets and nurses, to develop cytology skills, which are enjoyable and relatively easy to learn. He suggests self-examining slides in their lab, writing reports, and seeking feedback for skill improvement. David notes that mast cell tumours are an excellent starting point for cytology learning as they often feature distinctive "fried egg-like" cells with blue to purplish granules. However, expert consultation is crucial for tumours with unusual characteristics or more aggressive features.

The Necessity of Biopsies for Tumour Grading After FNAs

25.15 - Sue questions the necessity of biopsies after fine needle aspirates (FNAs) for tumour grading. David notes FNA's value in general practice and good correlation with histological grade. He emphasizes combining clinical tools and considering staging, especially for higher-grade tumours. For less aggressive cases, FNA of the draining lymph node may rule out lymph node involvement before surgery. David discusses grading schemes, including the pattern grading scheme and Kiupel system.

Chapter 3 – Mr and Mrs Outcome

Treatment Options for Mast Cell Tumours

29.55 - John inquires about mast cell tumour treatments and whether they're managed in primary vet settings or by specialists. David explains treatment involves addressing the local tumour through surgery or radiation therapy, with staging for potential metastasis. Medical therapies like chemotherapy or growth factor inhibitors are considered if metastasis is found. Emerging therapies like Tigilanol tiglate and Electro Chemotherapy are mentioned, particularly for challenging cases.

Prognosis of Mast Cell Tumours

35.52 - John inquires about mast cell tumour prognosis. David explains that low and intermediate-grade tumours have a generally favourable prognosis with surgery, even if some cells remain at the margins. However, high-grade tumours, especially if they've spread, often require ongoing medical therapy and monitoring, with potential recurrence.

Key Points on Dealing with Dog Lumps and Seeking Specialist Guidance

37.54 - Sue summarizes key points: Urges not to ignore lumps on dogs, as up to 50% can be malignant. Recommends consulting specialists like David instead of relying on online sources for accurate guidance and evolving treatment options. David appreciates the summary, emphasizing the dynamic nature of oncology and the limitations of online information.

https://www.liverpool.ac.uk/sath/about-us/

43.44: John wraps the pod with another daft questions.

Log this CPD with 1CPD here 

(00:00) John introduces the podcast and welcomes our guest for this episode - the founder of the Dermatology Referral Service in Glasgow, Peter Forsythe.

Chapter 1 – The Ears

(02:58) John welcomes Peter Forsythe, who talks about how he got involved in dermatology and how ear disease makes up half the caseload in the referral practice he works at.

(04:41) John asks why it is important dogs have clean ears and Peter discusses the long tube made up of the auricular and annular cartilages which are lines with glandular skin which produces wax - which combines with skin cells to make up what we know as wax. He says a build-up can alter the environment on the ear canal, increasing humidity and increasing the number of microbes such as bacteria and yeast, which - whilst normally present - can develop into an overgrowth or even infection. He also talks about the concretions, or balls of ear wax which can form adjacent to the tympanic membrane or ear drum, and they are called ceruminoliths and can sit on the ear drum and damage and even perforate it. So it is important to manage this ear wax and keep the ear clean.

(07:55) Sue asks about the ‘self cleaning’ mechanism the ear called epithelial migration and Peter describes this as similar to the shedding of cells we have on our continuously growing skin cells, but in the ear these have a sliding, upward motion to them as they do this, and this slowly carries cells and wax up and out the ear like a slow moving escalator – at the speed our nails grow at.

(09:49) Sue asks if this changes with age and Peter says there isn’t information on age changes, but in cases of inflammation or disease this is affected, slowing it down and then leading to increased build up of wax. Peter says the human ear produces 2 kilos of wax in a lifetime!

(11:32) Sue asks what Peter recommends to clients in terms of ear cleaning with puppies and he doesn’t recommend routine ear cleaning in puppies if they are healthy, as the mechanism is working well; however, he does think in those breeds where they are prone to ear disease, that it is good to get them used to you handling their ears at a young age.

Chapter 2 – The Cleaning

(13:34) Sue asks about hairy ear canals or plucking ears and Peter says in his view plucking hairy ear canals in poodles and bichons for example, where the hair can trap the wax, can irritate and inflame the ear and begin ear disease, so he wouldn’t pluck them. If the dog has got ear disease (otitis) then some plucking maybe necessary – but ear phobia – where a dog has had bad experiences and they won’t let people go near their ears, is more of an issue and plucking can lead to this. He would prefer then to begin cleaning if you can see wax building up. This is the same with a dog with a pendulous (flappy outer) ear (which can also contribute to ear disease) – but he does point out too much cleaning can overly wet the ear and cause more problems – so each case must be considered carefully.

(17:15) Sue asks as a pet owner who can see so many different ear cleaners, what can help you decide and what to look for and Peter divides these into two. Firstly softening or dissolving ear wax products called cerumenolytics, containing things like propylene glycol, mineral oils, glycerine; through to secondly salicylic acid or even stronger sodium docusate (DOSS) or carbamide peroxide (which is only recommended in anaesthetised dogs) which dissolves. Sue clarifies then this depends on how waxy the ear is as to which you reach for and Peter says it is recommended to talk to the vet about it rather than purchasing straight from the internet.

(21:10) John points out it is important then for any nurse or vet to have a good understanding of the ear cleaners on their shelves and Peter wholeheartedly agrees, saying for example a more water based ear cleaner being used to dissolve and remove wax doesn’t make sense and also cleaning isn’t comfortable for the dog; so it is important to demonstrate the use of a product to an owner, and give them tips such as warming the ear cleaner a little to make it more comfortable.

Chapter 3 – The Cleaners

(24:20) John asks about powders and Peter remembers when they were used more frequently, but he does not recommend them at all as they mix with the wax and make it stickier and dryer. John goes on to ask what changes in the ear once disease starts to set in; Peter says if a dog has had ear disease once, it is very likely to happen again and can happen repeatedly. Over time this changes detrimentally the ear canal; the lining becomes thicker and the tissues become swollen and oedematous, the glands become enlarged and even massive over time; all this narrows the ear canal and impairs the epithelial migration and so you have an increased build up or wax in a smaller canal and this favours the further build up of bacteria and/or yeast in the ear. He also says the ear drum can then weaken and even perforate, so a hole can appear and then infection can get into the middle ear which is both more serious and hard to treat. He points out if the ear disease being allowed to continue year on year this can then result in long term changes where the ear cartilage becomes calcified, so effectively into bone – at this point often only surgery can help.

(29:38) Sue mentions these dogs all have underlying issues which cause these ear problems, and flags this for a further podcast. Sue then asks about the cases where we have these changes and the presence of yeast and bacteria and asks if there should be cleaning in all of these cases; Peter replies that there is strong evidence to say that due to the increase in discharge they should all be having regular cleaning – as the normal treatment for these cases - antibiotic and or antifungal ear drops - need to be able to get to the lining of the ear through this discharge in order to work. So, they need cleaning prior to the drops going in. Sue asks if these are the antiseptic cleaners we would use and Peter agrees, saying you want the cleaner to both remove the wax build up but also have an antiseptic effect, he mentions isopropyl alcohol, para-chloro-meta-xylenol (PCMX) and in particular chlorhexidine with Tris EDTA as a common effective combination for these cases – which in some cases can resolve the disease when used as a sole treatment. Sue reflects that as in Scandinavia as heard on a previous SkinFlint, more thought is going into using these to avoid antibiotic use.

(32:47) Sue asks Peter what a practice would have as three key ear cleaners for stocking their pharmacy, Peter says three is a good number and they would want a soothing, wax softening cleaner for the low symptom waxy ears – such as a glycerine, propylene glycol or mineral oil with camomile for example. Then a more potent, cerumenolytic ear cleaner, possibly with a detergent such as DOSS or chlorhexidine or alcohol. Then the third would be an aqueous ear cleaner for use in the purulent, pus based discharge in severe cases such as a pseudomonas infection, and this would be the chlorhexidine and Tris EDTA combination as discussed.

(36:34) John wraps up and summarises the conversation.

(41:35) John asks his co-hosts the usual daft questions so we don’t take ourselves too seriously!

Log this CPD with 1CPD here 

(00:00) John introduces today’s guest - host of another veterinary dermatology podcast The Derm Vet, Ashely Bourgeois.

Chapter 1: UK vs US Dermatology

(02:50) Sue asks Ashley how she started out in podcasts and Ashley shares her story, wanting to stay involved in dermatology whilst also raising children and not wanting to lose that knowledge base, and helping  others in that kind of position.

(04:33) John asks Ashely and Sue what the difference between the UK and US in approach to dermatology. Sue says the approach is the same, but the system is slightly different and there isn’t so much of a referral process in the US as here in the UK. Ashley agrees, saying often people will come direct, but that they have good relationships with first opinion practices in order that clients are aware dermatologists exist.

(06:45) Sue says the board certified dermatologists exist in both regions, but in the UK we have an intermediate tier of advanced practitioners which doesn’t exist in the states; therefore asking Ashley if there are any areas in the US which aren’t covered well geographically with specialists. Ashley says there are areas without specialists, and there is work to see if they can develop better coverage; including the possibility of telemedicine in for example a state that doesn’t have dermatologists.

(08:58) Sue asks if the rules around dermatology prescribing through telemedicine differs state to state and Ashley confirms this, saying in her state for example, they must see a client at least once a year whereas in other states this is possible long term remotely.

Chapter 2: UK vs US Antibiotic Use

(11:30) Ashley then asks Sue if it differs in relation to staphylococcus infections in the UK and US and Sue says it really does, and also across Europe from the UK. She points out in Scandinavia they hardly use antibiotics at all and use antiseptics much more, and this seems to really correlate to having less resistance. Sue asks for example if Ashely would use vancomycin and Ashely says whilst she hasn’t for this one she has had to use rifampin and chloramphenicol. She reflects there is a shift in the mindset with the use of antibiotics because of the number of times they will only have one or two choices left due to resistance.

(14:45) Sue asks if it is right you can buy neomycin, polymyxin, bacitracin over the counter and Ashely says you can for topicals, and said she even had a client who had fish antibiotics they were giving to their dog whenever they felt there was an infection. Sue reflects what would be available by comparison in the UK.

Chapter 3: UK vs US In Practice

(17:17) John asks whether a clients expectation would differ in terms of approach to a skin case in the states than in the UK and Ashley says there is much the same issue in terms of clients not understanding the long term nature of skin management, particularly in allergy and also the multimodal approach; where often more than one therapy is going to manage the patients skin. She is always quick to point out to owners these cases will change and even when well managed, this will change and they will flare up.

(20:14) John reflects that in the US the Vet nurses or Vet Techs as they are called there are still as important to case management as here in the UK and Ashely passionately agrees, saying they are critical to the solidification of a case management – instilling confidence in the owners to the treatment plan long term. They also catch mistakes and understand the cases very well.

(23:05) John asks Ashely about the education side in terms of the difference with logging CPD and education. Ashley says the regulations are quite strict in terms of whether she can talk off label at lectures and online and her and Paul reflect on some of these aspects.

Chapter 3: UK vs US Dermatology Top Trumps

(26:27) Sue asks Ashley for most common presentations and Ashley and Sue spend some time reflecting on the differing cases and presentations seen both in the US and UK. Where Ashely is in the US the climate is similar but Sue reflects it is interesting how the diseases are so different.

(33:50) John wraps the podcast by asking Sue and Ashley what their favourite and least favourite disease it. Pemphigus comes out well whilst sterile nodular panniculitis and bald Pomeranians/alopecia X and lick granulomas really don’t!

Visit Ashley’s Website HERE

Search The Derm Vet Podcast on your podcast platform, or follow the link HERE

Ep.16 Show Notes

In this Skin Flints episode, Sue, John and Paul welcomed Dr Arielle Griffiths to the platform to discuss a very topical subject - sustainable pet food.

(00:00) Introduction

Chapter 1: “Understanding the Urgency: Why Sustainable Food is Necessary for Our Pets”

(03:44)  John welcomes Arielle to the pod, who talks about her work in the industry and in setting up the Sustainable Pet Food Association. As a GP vet she became involved in nutrition and did extensive research before also becoming environmentally and sustainably focused as a result of seeing a change in the world.

(07:31) Sue asks Arielle to clarify what is meant by obesity-based diets and Arielle says this is where owners are (through love) overfeeding their pets and potentially causing arthritis, heart disease and a number of conditions relating to the excess weight. This tipped her to realise the use of plants as a base in food can really help, which was a big factor in her  becoming vegan herself.

(09:08) Sue clarifies we are talking about people feeding too much or an imbalanced diet and the carbon footprint of that diet – and that we are discussing dogs here and not cats. Arielle says that the need for palatability in foods has resulted in an excess of protein in the diet and more meat being used than needed, affecting the sustainability. She shared that wet, meat-based diets have the largest carbon footprint, including raw lean diets – with one study in Brazil demonstrating a dog on this diet matched that of a human in that country.

Chapter 2: "Exploring the Landscape: What Constitutes Sustainable Food?"

(11:49) John asks why vegetarian or vegan food is a more sustainable option and Arielle says it is proven that animal agriculture for the use in pet food accounts for 2.5 - 3% of the entire carbon footprint of the world. This comes from deforestation to provide this food and the by-products of the food as a result of the market.

(13:40) Sue clarifies this as methane production from the animals used increasing the carbon emissions along with the deforestations. Livestock accounts for over 70% of global farming land use but only produces 18% of the world’s calories and 37% of total protein - with dog and cat food being equivalent to an entire country’s worth of production. But Arielle says the health benefits are what turned her more to vegetable based foods. 

(15:29) Sue comments on the information on the human side for the health benefits, with more GPs suggesting it – she asks if there is evidence to support this on the pet side. Arielle says there is and comments on how in the 27,000 years of domestic evolution dogs have developed to require 52% of their diet to be carbohydrate due to the change in their genes over that time compared to the wolf they descended from, which only needs 1.2% carbohydrate. She also says dogs 3,000 years ago were primarily plant based.

(17:09) John asks if the theory of raw feeding being more natural for dogs is therefore unmerited and Arielle agrees, explaining that dogs obviously love eating food like this which is the success of the industry – but in terms of the environment there is significant evidence that resistant bacteria has been shown to be happening as a result of raw feeding, as well as it not being healthy for the dog. And she reiterates - a dog is not a wolf!

(19:18) John goes on to clarify Arielle is advocating a formulated dog food which is vegetable based and asks if it could be insect based. Arielle says it could and there are a number of companies for this, but she focuses on vegetable based and insects are just using another way of recycling protein and therefore whilst they are more substantiable – they are not as much so as the vegetable equivalents. She mentions how she was one of three vets speaking on the subject at London Vet Show along with Professor Andrew Knight and Dr Mike Davies - talking about animal nutrition and the evidence for vegetable based diets, which previously had looked to have a vegan diet, but a new independent study from Australia and Mexico reviewing all the papers indicated the evidence is sound. She argues now we know they are healthier for our pets and our planet there is an urgency.

Chapter 3: "Making Informed Choices: Considerations for a Sustainable Diet"

(24:40) Sue asks what we do about different life stages and different conditions and Arielle says there is a puppy plant based food and a senior plant based food – and in fact any plant based food is good for senior dog.

(26:12) Sue asks about particular conditions as well (e.g.) skin conditions and Arielle says she’s getting 2 or 3 people a day asking her to transition their dogs from meat diets because of an intolerance to it, and much has been shown to evidence the gut microbiome health being linked to that of the sin and therefore the skin health.

(28:19) Sue asks if you can transition to a plant based diet overnight. Arielle advises that the cases where they are really uncontrolled and unhappy on the food can transition overnight with a care to not over feed. But for the majority of dogs - as with any dietary change - a slow transition over 2-3 weeks is better; 4-5 weeks for raw fed dogs, in order to allow the gut to adapt to the change.

(29:29) Sue asks about the evidence suggesting grain free diets can lead to heart disease and Arielle says this came about in 2018 with increased instances of dilated cardio myopathy in breeds you wouldn’t normally see. She explains this is a result of substitute ingredients and is resolved with the addition of taurine to diets – which is an important reason to use a formulated diet. The number of cases has now dropped as a result of these changes.

(32:45) John wraps the conversation and asks Arielle if there are any resources to highlight and Arielle again recommends the Sustainable Pet Food Association as a great resource to find out more, and find the right food.

(36:18) Outro – Sue raps up as an ever-wise voice of reason.

(40:57) John asks Sue and Paul - Beef or beans?!

Ep.15 Show Notes

In this Skin Flints episode, the team were delighted to host one of the giants of the equine world - the brilliant Derek Knottenbelt (or Knotty, as he is also known).

Log this CPD with 1CPD here 

Chapter one: Knotty

(03:49) Sue introduces Derek Knottenbelt who gives his background in the industry and his practical emphasis.

(05:09) Sue asks Derek "what is a sarcoid?". He describes it as a reactive skin tumour – so skin cancer is the best way to think about it and not viral as it has been before which has resulting in an incorrect approach; a multi-morphology skin tumour affecting all equid species and continuing to puzzle the scientific world.

(07:00) Sue asks whether it can be contagious given it is a tumour and Derek says that it is his contention that it is transmissible with circumstantial evidence to suggest this, but the mechanism for this is very little understood – it has some relationship with the bovine papilloma virus.

(08:06) Sue asks flies are spreading this and Derek says it is – where sarcoids occur tend to be where the skin is thin – where flies can feed with impunity – where it sweats and there is less hair and therefore where flies feed. Derek doesn’t believe it is the biting fly that transmits it – but a surface feeding fly which feeds on a sarcoid and then transfers the sarcoid element into the site of skin trauma on another horse – which could include where a biting fly had caused tissue damage.

(10:12) Sue says this would fit with periocular sarcoids as flies tend to feed there and Derek again agrees, saying wherever sarcoids occur rarely, they are always associated with wounds which further demonstrates this.

Derek uses the analogy of surface feeding flies being like teenagers going to MacDonalds, where the food is greasy, warm and available at almost no cost – whereas biting flies are like Richard Branson who wouldn’t dream of going to MacDonalds but a 5 star Michelin star restaurant – before then saying sometimes the biting flies go there after and have a pub drink and transfer the sarcoid.

This all fits the epidemiology of the disease – but the process of exactly how this happens and the link to bovine papilloma virus is not yet fully understood.

(12:36) John summarises the conversation so far and Derek goes on to show how in 1985 in a survey 2.5% of British horses had sarcoids, with an average of 2.5 sarcoids each. In 2018 this had risen to 8% of British horses with an average of 24 sarcoids each - so this disease is steadily increasing.

Chapter 2: Sarcoidy

(15:06) John asks if there are any breeds, ages or predispositions which are more susceptible and Derek says that whilst some studies have demonstrated this he does not think it is so simple having seen sarcoids in just about every breed that is available – he says there are genes which impart susceptibility as there have been outbreaks within families of horses. So it is very difficult to isolate. He also studied age of onset within a study of close to 30,000 horses and the numbers merely mimicked the population – so no definitive evidence, and he has seen 40 year old and 17 day old horses with sarcoids. He is more convinced of conditional, situation and environmental factors over any of age, breed, gender and colour.

(19:05) Sue asks about sarcoids themselves – what do they look like? Derek says it is often misdiagnosed as something else because of how multiformal it is. Because it is a tumour of fibroblasts and not epithelial cells often what you see bears no relation to what you would perceive as a fibroblastic tumour. This is because of the effect of the viral component on the disease and the impact this has on the surround tissues.

So firstly the occult form of sarcoid is not the occult tumour – but may contain the tumour – and this must be kept in mind. He goes on to say the circular nature of this form is in effect a result of the mediators diffusing out from the centre. Then the centre begins to develop and become more dermal / epidermal and morphs into something more like a wart, but is not a wart but a ‘vericosal, wart like tumour’, the next from of sarcoid.

Then the next stage/form is either a hard mass-like nodule of fibroblasts called a type A nodule and is completely subcutaneous, or a type B nodule which is attached to the skin dermis. These are easy to identify and are very easily characterised.

Then there is a fleshy form which is very aggressive, vascularised and ulcerated (usually infected) tumour which appears like granulation tissue.

Derek says each of these types has its own potential differential diagnosis which makes them very open to misdiagnosis.

(27:07) Sue asks what causes the transition of one for, to another and if that should point to biopsy. Derek says that with the age of the tumour there is a constant progression, and traumatising the lesion will only accelerate this process (such as with a harness or a buckle, or the movement of the skin in mobile areas). This means biopsy, whilst definitely useful, is only worth doing if you have a plan of what to do when you find it is a sarcoid - as it will otherwise just exacerbate the problem.

Chapter 3: Treatmenty

(30:53) John asks then what the treatments are for a sarcoid and Derek says superficial lesions require less interventions and a 5% or 10% floriorisol and if this does not work a imiquimod – but it is important to bear in mind they are still dangerous because they don’t like being treated, so if you aren’t successful they worsen and a real determination is needed with the disease to keep progressing to the next step. A surgical or laser excision could be considered but it is critical these are sent for pathology for margins to know if you have removed it all – as not doing so require further action.

(35:04) Sue asks what the prognosis is, with good margins and without; Derek says a successful, safe margin of removal is a good base for a start – however there can be tumour cells seeded during surgery and indeed after on the scar from fly attack -so this must still be treated cautiously. If you haven’t got a successful margin you will get deep root recurrence – so by the time you see the tumour it will be twice as big. In this instance Derek likes multimodal therapy, using immunologic methods such as immunosiden, BSG or radiation, or local chemotherapy. Derek goes on to discuss types of localised chemotherapy – also pointing out you can add other therapy such as cryosurgery on top as well. Each time you are adding on a little prognosis – but Derek points out the only thing predictable about a sarcoid is that it is unpredictable and there are over 40 treatments to consider in managing these with new therapies coming out all the time and he lists some of these, but warns against the nonsense brigade – with poor evidence based treatments on the market such as marmite or toothpaste – successes in these instances are coincidental to spontaneous resolution.

(44:55) John wraps up the conversation and summarises, while sue mentions Equine Medical Solutions (Derek’s app).

Outro

(46:58) John brings the podcast to a close by putting Sue and Paul on the spot was another probing question...

In this episode of the Skin Flint podcast, Sue, John and Paul welcome Katarina Varjonen to the platform to discuss the Scandinavian approach to responsible veterinary antibiotic usage.

Log this CPD with 1CPD here

(02:46) Katarina introduces herself and her experience as a dermatologist; Sue clarifies she is also the incoming president of the European Society of Veterinary Dermatology.

(04:00) Sue talks Katarina's career, working in Scandinavia, the UK and the USA, commenting on how good Scandinavia is on managing antibiotic usage. Sue then asks why responsible antibiotic use is important and Katarina says the one health consideration ties in and is really important across the profession in order to avoid using them longer than needed to prevent resistance. She feels most countries have put a lot of work into eliminating unnecessary use.

(06:39) Sue asks Katarina to outline the advanced approach Scandinavia has to this and Katarina says antibiotics are not completely off limits, but the guidelines are strict for recommendations – as well as limitations to what is available on the market. So for a number of years now fluroquinolones and 3rd generation cephalosporins are limited to life threatening situations, requiring culture tests as proof. Sue clarifies these are classed as critically important antibiotics in humans.

(08:23) John says this sounds quite extreme in comparison to what we do in the UK and asks if this would be considered a few years ahead of the UK and what is happening in the US. Katarina comments on it more as a cultural difference, feeling that the smaller industry in Scandinavia has helped to spread the message from within, along with the government and health sector working hard to spread the message to the public. As a result they don’t get pressure so much from clients to use the antibiotics in the first place.

(10:19) Sue asks if it is easier to treat a disease in Scandinavia because there is less resistance to antibiotics, or whether it is harder because you have less access to antibiotics. Katarina says that actually they still have the same access, but the big difference in the case management is that in Scandinavia they are far more keyed into preventative approach to a disease, meaning the cases are better managed in the first place and therefore cases are less severe from the outset.

(12:10) John asks if this comes at all from the owners side, with them being more in-tune with identifying issues early and Katarina doesn’t believe so – she feels this comes entirely from the veterinary side.

Chapter 2 – The Prologue to a Case

(13:52) John asks Katarina to share what things would help with that early identification and Katarina says scratching and head shaking is the early sign, and whilst the approach to these first symptoms will be the same for treatment, the conversation about underlying causes is begun at this stage, which is almost always allergy. Katarina herself describes this to owners as the dog equivalent of allergic eczema but in the ear.

(16:20) Sue asks Katarina to talk through her approach to a case. Katarina says she would start by feeling the ear canal on the outside, is it firm or soft to suggest issues – it also helps the dog to get used to being handled. Then she has a look with an otoscope down the ear if the dog tolerates - or she may sedate at this stage if not – in order to examine and perform cytology. If the canal is inflamed she will go to cleaners and anti-inflammatories to open up the canal, even before thinking about treatment of the infection.

(18:07) Sue asks Katarina to clarify what is meant by Cytology and Katarina describes this as the basic and easy to perform diagnostic tool for these cases, using a Q-Tip (cotton bud) to gather material from the upper ear canal and roll onto a microscope slide before staining with Diff Quick (or similar) to look for bacteria, round or rod shaped, yeasts or inflammatory cells. As well as assessing the level of the load.

(19:43) John says this sounds quite straightforward, asking if this is something a specialist needs to do or whether a non-specialist / nurse could perform this; Katarina says that actually even in referral practice it is mostly the veterinary nurse who will do this, taking the sample, staining and even examining under the microscope. It is not specialist cytology and only takes a couple of minutes. Katarina shares that for fractious dogs a clean finger rather than a cotton bud, into the entry to the canal and rolled onto a slide will also work.

(23:18) John asks if the cytology is something that is done just initially, or whether this would be done in follow-ups and Katarina shares that she performed cytology all the time at every visit as standard. This is because as she is using anti-inflammatories and other treatments she will see an improvement visually so cytology is the only way to know whether she is resolving the actual infection.

(23:57) Sue clarifies then the switch from treatment to maintenance would be made once she observes the levels of microbes dropping to what would be considered normal rather than symptoms.

Chapter 3 – Chapter and Verse on Treatment

(25:21) Sue asks what kind of actives (stuff in the products) Katarina would use in terms of anti-inflammatories and cleaners having done cytology and found microbes present. Katarina says the texture of the discharge from the ear, whether this is fatty/lipid or ceruminous/waxy in which case she would reach for a squalene based cleaner or if it is a liquid based discharge with pus forming she would use a chlorhexidine/tris EDTA based cleaner. If she suspects a biofilm in the ear as well from slimy discharge she would add in an an-acetal cysteine flush to the cleaner.

(26:59) Sue asks what anti-inflammatories she would use and Katarina clarifies this would depend on thickening of the skin in the ear – so if the ear is stenosed/narrow she would use oral steroids in addition to topical steroid in the ear, but if it was more minor she would only use a topical. This also reduces pus formation. Sue asks how you would use a topical steroid without using the other antibiotic and antimycotic treatments that are in licensed, steroid containing topical products. Katarina says she would use a steroid on its own without the others even though the licensed products are next on the cascade, because the antibiotic stewardship wins over the grey zone element of the cascade in these instances. John summarises this and Katarina clarifies that the preparation of the ear and selection for antibiotics is critical to making sure that when she does then reach for it, it is effective as it can possibly be.

(32:33) John asks what ear cleaners when used in preparation of the ear also have some effect on the microbes we are seeing in the ear at the same time and Katarina says that actually even just cleaning out the ear gives the body and immune system a chance to start helping in fighting the infection – so begins the process. Then the likes of chlorhexidine and Tris EDTA combined, and an acetal cysteine help further to fight this if they are present in the cleaners, hypochlorous acid as well.

(35:30) Sue asks if Katarina feels that maybe in the UK we are tempted to reach for antibiotics too soon and Katarina says often we feel safer doing this because we want to manage these cases, and it is a big step to understand there are steps we can take first before assessing to see how well they have worked, in order to manage the cases which don't need antibiotics and identify the ones which do. She would try for two weeks generally first before reaching for antibiotics if there hasn’t been a reduction in the number of microbes in the ear.

Sue and Katarina summarise the importance of the use of topicals to try and push forward the appropriate use of antibiotics.

(37:40) John asks one final question to Sue and Katarina on how important this is, whether people need to really take this seriously and whether there should be any pressure from the authorities on this. Katarina says we do need to take it seriously, perhaps less to with topical antibiotics than systemic (oral/injectable), but this is still very important to strive for this. Sue says that the use of cytology is critical and underperformed in terms of understanding whether there is infection present in the first place, and whether we have completely eliminated the infection at the end of treatment. We need these drugs and we turn on the resistance when we feed the bugs these drugs, and we are moving in the right direction together. Katarina echoes this, showing a lot has happened even in the last few years.

Outro

(43:55) John and Sue wrap up before John asks his usual silly question (ask your own sensible or silly question by emailing [email protected] ) – Sue and Paul are asked what frustration they would most like a drug to rid their lives of, walking into a put down by Paul!